Beximco Pharmaceuticals Limited Sunday announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. This follows the approval of Olopatadine (0.1 per cent solution) by Health Canada during the last financial year and is the first time a pharmaceutical product from Bangladesh has been launched in this North American country. According to IMS data, the current market size for Olopatadine eye drops (including all strengths) in Canada is $14 million. The first consignment was delivered Saturday.
© 2023 - All Rights with The Financial Express